Prosecution Insights
Prosecution Insights
33 pending office actions • 1 client • 29 examiners • 21 art units • 0 of 33 (0%) have an AI response strategy ready • 34 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 33 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 33 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 4 (12%) |
| §103 only | 18 (55%) |
| §102 only | 5 (15%) |
| §112 only | 4 (12%) |
| Double-patenting + other | 1 (3%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUNTS, GARY W | 3 | 58.9% | +29.3% |
| MARCSISIN, ELLEN JEAN | 2 | 32.8% | +48.6% |
| NGUYEN, NAM P | 2 | 54.7% | +46.4% |
| JORGENSEN, ABBY A | 1 | 73.6% | +16.7% |
| DOWNING, SAVANNAH STARR | 1 | 75.7% | +5.9% |
| HAUK TEODORO, PRICILA NMN | 1 | 100.0% | +0.0% |
| BROTHERS, LAURENCE RAPHAEL | 1 | 87.1% | +17.8% |
| MOAZZAMI, NAGHMEH NINA | 1 | 71.7% | +42.8% |
| HRANEK, KAREN AMANDA | 1 | 36.0% | +46.8% |
| SINES, BRIAN J | 1 | 80.4% | +4.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18352183 | PROGNOSTIC VALUE OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING STABLE DISEASE | SINES, BRIAN J | 30d overdue |
| 18560126 | METHOD FOR OPERATING A LABORATORY AUTOMATION SYSTEM, LABORATORY AUTOMATION SYSTEM, AND LABORATORY IN-VITRO DIAGNOSTIC SYSTEM | BROTHERS, LAURENCE RAPHAEL | 12d |
| 18542054 | THERMOSTABLE AFFINITY POLYPEPTIDES | HAUK TEODORO, PRICILA NMN | 57d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17575120 | S100A9 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS | IVICH, FERNANDO NMN | 19d overdue |
| 17575202 | S100A12 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS | MONTGOMERY, ANN Y | 28d |
| 17772959 | SEPSIS MANAGEMENT | COUNTS, GARY W | 29d |
| 18017073 | GDF-15 FOR PREDICTING THE DISEASE SEVERITY OF A PATIENT WITH COVID-19 | ZOU, NIANXIANG | 61d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17891458 | IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING | MARCSISIN, ELLEN JEAN | 51d overdue |
| 18556849 | INFORMATION PROCESSING DEVICE FOR PROVIDING REFERENCE INFORMATION RELATING TO DIAGNOSIS OF THYROID DISEASE | HRANEK, KAREN AMANDA | 25d overdue |
| 17162140 | Use of Biomarkers in the Assessment of the Early Transition from Arterial Hypertension to Heart Failure | MARCSISIN, ELLEN JEAN | 19d overdue |
| 18561621 | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS | COUNTS, GARY W | 8d overdue |
| 18649151 | TRANSPORT DEVICE AND LABORATORY SAMPLE DISTRIBUTION SYSTEM | JORGENSEN, ABBY A | 3d overdue |
| 18560126 | METHOD FOR OPERATING A LABORATORY AUTOMATION SYSTEM, LABORATORY AUTOMATION SYSTEM, AND LABORATORY IN-VITRO DIAGNOSTIC SYSTEM | BROTHERS, LAURENCE RAPHAEL | 12d |
| 17821951 | TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION | COUNTS, GARY W | 13d |
| 15892829 | ALKALINE PRETREATMENT OF PARVOVIRUSES FOR IMMUNOASSAYS | NGUYEN, NAM P | 26d |
| Client (Assignee) | Pending OAs |
|---|---|
| Roche | 33 |
| Art Unit | Apps |
|---|---|
| 1678 | 7 |
| 1677 | 3 |
| 1796 | 2 |
| 1797 | 2 |
| 1758 | 2 |
| 1687 | 2 |
| 3651 | 1 |
| 2884 | 1 |
| 1645 | 1 |
| 3655 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18649151 | TRANSPORT DEVICE AND LABORATORY SAMPLE DISTRIBUTION SYSTEM | Roche Diagnostics Operations, Inc. | JORGENSEN, ABBY A | 3651 | §102 | Final Rejection | 3d overdue | Pending | Apr 29, 2024 |
| 18620273 | LIGHT SOURCE FOR GENERATING ILLUMINATION LIGHT | Roche Diagnostics Operations, Inc. | DOWNING, SAVANNAH STARR | 2884 | §103 | Final Rejection | 39d | Pending | Mar 28, 2024 |
| 18542054 | THERMOSTABLE AFFINITY POLYPEPTIDES | Roche Diagnostics Operations, Inc. | HAUK TEODORO, PRICILA NMN | 1645 | §112 | Non-Final OA | 57d | Pending | Dec 15, 2023 |
| 18561621 | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS | Roche Diagnostics Operations, Inc. | COUNTS, GARY W | 1678 | §103 | Non-Final OA | 8d overdue | Pending | Nov 16, 2023 |
| 18560126 | METHOD FOR OPERATING A LABORATORY AUTOMATION SYSTEM, LABORATORY AUTOMATION SYSTEM, AND LABORATORY IN-VITRO DIAGNOSTIC SYSTEM | Roche Diagnostics Operations, Inc. | BROTHERS, LAURENCE RAPHAEL | 3655 | §103 | Non-Final OA | 12d | Pending | Nov 10, 2023 |
| 18557895 | GDF15 MARKER PANELS FOR EARLY DETECTION OF SEPSIS | Roche Diagnostics Operations, Inc. | MOAZZAMI, NAGHMEH NINA | 1652 | DPOther | Non-Final OA | 61d | Pending | Oct 27, 2023 |
| 18556849 | INFORMATION PROCESSING DEVICE FOR PROVIDING REFERENCE INFORMATION RELATING TO DIAGNOSIS OF THYROID DISEASE | Roche Diagnostics Operations, Inc. | HRANEK, KAREN AMANDA | 3684 | §103 | Non-Final OA | 25d overdue | Pending | Oct 23, 2023 |
| 18352183 | PROGNOSTIC VALUE OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING STABLE DISEASE | Roche Diagnostics Operations, Inc. | SINES, BRIAN J | 1796 | §102 | Non-Final OA | 30d overdue | Pending | Jul 13, 2023 |
| 18338633 | METHOD FOR PREPARING HIGHLY POROUS POLYMER PARTICLES FOR DIAGNOSTIC APPLICATIONS | Roche Diagnostics Operations, Inc. | LEAVITT, MORDECAI MIZANI | 1742 | Other | Non-Final OA | 56d | Pending | Jun 21, 2023 |
| 18337018 | LC-MS METHOD FOR DETECTING AND QUANTIFYING 11-OXYGENATED STEROIDS | Roche Diagnostics Operations, Inc. | SODERQUIST, ARLEN | 1797 | §103 | Non-Final OA | 21d | Pending | Jun 18, 2023 |
| 18333347 | INTERFERENCE MONITORING FOR PROVIDING A VERIFIED ANALYTE MEASUREMENT | Roche Diagnostics Operations, Inc. | HYUN, PAUL SANG HWA | 1796 | §103 | Non-Final OA | 33d | Pending | Jun 12, 2023 |
| 18312442 | DERIVATIZATION OF AT LEAST ONE ANALYTE OF INTEREST FOR MASS SPEC MEASUREMENTS IN PATIENT SAMPLES | Roche Diagnostics Operations, Inc. | XU, XIAOYUN | 1797 | §103 | Non-Final OA | 2d overdue | Pending | May 04, 2023 |
| 18309985 | TIMP1 AS A MARKER FOR CHOLANGIOCARCINOMA | Roche Diagnostics Operations, Inc. | DENT, ALANA HARRIS | 1643 | §102 | Non-Final OA | 20d | Pending | May 01, 2023 |
| 18306195 | DETECTION OF AN ANALYTE OF INTEREST BY NANOESI MASS SPECTROMETRY | Roche Diagnostics Operations, Inc. | FRITCHMAN, REBECCA M | 1758 | §103 | Final Rejection | 21d | Pending | Apr 24, 2023 |
| 18017073 | GDF-15 FOR PREDICTING THE DISEASE SEVERITY OF A PATIENT WITH COVID-19 | Roche Diagnostics Operations, Inc. | ZOU, NIANXIANG | 1671 | §101 | Non-Final OA | 61d | Pending | Jan 19, 2023 |
| 17916251 | A METHOD OF ASSESSING A FEMALE'S RISK OF HAVING PCOS AS WELL AS PRODUCTS AND USES RELATING THERETO | Roche Diagnostics Operations, Inc. | VOLKOV, ALEXANDER ALEXANDROVIC | 1677 | §103 | Non-Final OA | 4d overdue | Pending | Sep 30, 2022 |
| 17907039 | CORONA NUCLEOCAPSID ANTIGEN FOR USE IN ANTIBODY-IMMUNOASSAYS | Roche Diagnostics Operations, Inc. | JOHANSEN, PETER N. | 1644 | §103 | Non-Final OA | 8d | Pending | Sep 22, 2022 |
| 17931993 | CARRY-OVER MONITORING | Roche Diagnostics Operations, Inc. | HILL, GRACELYN MARKHAM | 1685 | §103 | Non-Final OA | 13d | Pending | Sep 14, 2022 |
| 17821951 | TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION | Roche Diagnostics Operations, Inc. | COUNTS, GARY W | 1678 | §112 | Final Rejection | 13d | Pending | Aug 24, 2022 |
| 17891458 | IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING | Roche Diagnostics Operations, Inc. | MARCSISIN, ELLEN JEAN | 1677 | §103 | Non-Final OA | 51d overdue | Pending | Aug 19, 2022 |
| 17814332 | SAMPLE INPUT INTERFACE | Roche Diagnostics Operations, Inc. | CHIU, MAY LEUNG | 1758 | §102 | Non-Final OA | 54d | Pending | Jul 22, 2022 |
| 17838568 | PARTICLE-BASED IMMUNOASSAY USING A PEGYLATED ANALYTE-SPECIFIC BINDING AGENT | Roche Diagnostics Operations, Inc. | NGUYEN, NAM P | 1678 | §103 | Non-Final OA | 34d | Pending | Jun 13, 2022 |
| 17772959 | SEPSIS MANAGEMENT | Roche Diagnostics Operations, Inc. | COUNTS, GARY W | 1678 | §101 | Non-Final OA | 29d | Pending | Apr 28, 2022 |
| 17575202 | S100A12 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS | Roche Diagnostics Operations, Inc. | MONTGOMERY, ANN Y | 1678 | §101 | Non-Final OA | 28d | Pending | Jan 13, 2022 |
| 17575120 | S100A9 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS | Roche Diagnostics Operations, Inc. | IVICH, FERNANDO NMN | 1678 | §101 | Final Rejection | 19d overdue | Pending | Jan 13, 2022 |
| 17643559 | SENSOR DEVICE AND METHOD OF USE | Roche Diagnostics Operations, Inc. | WOITACH, JOSEPH T | 1687 | §103 | Final Rejection | 70d overdue | Pending | Dec 09, 2021 |
| 17447844 | METHOD FOR DETERMINING AT LEAST ONE STATE OF AT LEAST ONE CAVITY OF A TRANSPORT INTERFACE CONFIGURED FOR TRANSPORTING SAMPLE TUBES | Roche Diagnostics Operations, Inc. | SKIBINSKY, ANNA | 1635 | §103 | Final Rejection | 16d | Pending | Sep 16, 2021 |
| 17360121 | DETECTION OF BACTERIAL (MOLLICUTIES) CONTAMINATION | Roche Diagnostics Operations, Inc. | BERTAGNA, ANGELA MARIE | 1681 | §103 | Non-Final OA | 14d | Pending | Jun 28, 2021 |
| 17186163 | THYMIDINE KINASE (TK-1) IN PROGNOSTIC INDICES FOR DLBCL | Roche Diagnostics Operations, Inc. | PULLIAM, JOSEPH CONSTANTINE | 1687 | §103 | Final Rejection | 56d overdue | Pending | Feb 26, 2021 |
| 17162140 | Use of Biomarkers in the Assessment of the Early Transition from Arterial Hypertension to Heart Failure | Roche Diagnostics Operations, Inc. | MARCSISIN, ELLEN JEAN | 1677 | §112 | Non-Final OA | 19d overdue | Pending | Jan 29, 2021 |
| 17126439 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | Roche Diagnostics Operations, Inc. | ANGELL, JON E | 1637 | §102 | Final Rejection | 16d | Pending | Dec 18, 2020 |
| 16008281 | FKBP DOMAIN WITH TRANSGLUTAMINASE RECOGNITION SITE | Roche Diagnostics Operations, Inc. | DABKOWSKI, ERINNE R | 1654 | §112 | Non-Final OA | 42d overdue | Pending | Jun 14, 2018 |
| 15892829 | ALKALINE PRETREATMENT OF PARVOVIRUSES FOR IMMUNOASSAYS | Roche Diagnostics Operations, Inc. | NGUYEN, NAM P | 1678 | §103 | Final Rejection | 26d | Pending | Feb 09, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial